<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>OTCMKTS-Listed — Portfolio on 6ix</title>
<link>https://6ix.com/p/otcmkts-listed</link>
<description>Top companies trading on OTCMKTS, ranked by market cap.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 06:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/portfolio/otcmkts-listed" rel="self" type="application/rss+xml" />
<item>
<title>Genflow Biosciences Plc: Expansion of Confidentiality Agreements</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/expansion-of-confidentiality-agreements</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/expansion-of-confidentiality-agreements</guid>
<pubDate>Tue, 28 Apr 2026 06:00:00 GMT</pubDate>
<description>Genflow Biosciences Plc has expanded its confidential agreements with Tier-1 animal health companies to include additional parties for the review of data from its canine SIRT6 cent gene therapy program, building on positive preliminary interim results reported in February 2026. These new agreements, alongside existing ones, indicate a growing third-party evaluation of the company's technology and data, though these interactions remain exploratory. The company is encouraged by these discussions a</description>
</item>
<item>
<title>Farfetch Limited: Coupang to Announce First Quarter 2026 Results on May 5, 2026</title>
<link>https://6ix.com/company/farfetch-limited/news/coupang-to-announce-first-quarter-2026-results-on-may-5-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/farfetch-limited/news/coupang-to-announce-first-quarter-2026-results-on-may-5-2026-1</guid>
<pubDate>Tue, 21 Apr 2026 20:05:00 GMT</pubDate>
<description>SEATTLE, April 21, 2026--Coupang to Announce First Quarter 2026 Results on May 5, 2026</description>
</item>
<item>
<title>Genflow Biosciences Plc: Genflow Biosciences PLC Announces Strategic Technology Collaboration</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-strategic-technology-collaboration</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-strategic-technology-collaboration</guid>
<pubDate>Mon, 20 Apr 2026 06:00:00 GMT</pubDate>
<description>Genflow Biosciences Enters Strategic Technology Collaboration with Acuitas Therapeutics - Fully Funded, Non-Dilutive Access to World-Class LNP Delivery Platform LONDON, UK / ACCESS Newswire / April 20, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ...</description>
</item>
<item>
<title>Genflow Biosciences Plc: International Patent Publication</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/international-patent-publication</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/international-patent-publication</guid>
<pubDate>Mon, 13 Apr 2026 06:00:00 GMT</pubDate>
<description>Genflow Biosciences Plc has announced the international publication of its Patent Cooperation Treaty application, WO 2026/062177 A1, which expands protection for its SIRT6-based muscular disease program, specifically targeting frailty syndrome and sarcopenia. This publication broadens the potential protection of Genflow's SIRT6 platform beyond longevity and metabolic applications, strengthening its intellectual property estate and supporting future development and partnering opportunities in mul</description>
</item>
<item>
<title>Genflow Biosciences Plc: Update on the Dog Study</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/update-on-the-dog-study</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/update-on-the-dog-study</guid>
<pubDate>Wed, 08 Apr 2026 07:55:00 GMT</pubDate>
<description>Genflow Biosciences Plc announced sustained positive safety and efficacy results three months post-dosing in its SLAB trial for the SIRT6 centenarian gene therapy in aged dogs, with no adverse events observed and previously reported improvements maintained. The trial, which is ongoing and expected to conclude in July 2026, is providing early evidence of the therapy's durable effects, contrasting with expected age-related decline in control animals. Further mechanistic insights are anticipated fr</description>
</item>
<item>
<title>Regional Health Properties, Inc.: Regional Health Properties Reports Fourth Quarter 2025 Results</title>
<link>https://6ix.com/company/regional-health-properties-inc/news/regional-health-properties-reports-fourth-quarter-2025-results</link>
<guid isPermaLink="true">https://6ix.com/company/regional-health-properties-inc/news/regional-health-properties-reports-fourth-quarter-2025-results</guid>
<pubDate>Tue, 07 Apr 2026 14:05:00 GMT</pubDate>
<description>Regional Health Properties Reports Fourth Quarter 2025 Results.</description>
</item>
<item>
<title>Genflow Biosciences Plc: Total Voting Rights</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/total-voting-rights-828</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/total-voting-rights-828</guid>
<pubDate>Tue, 31 Mar 2026 06:00:00 GMT</pubDate>
<description>Genflow Biosciences plc has announced that as of 31 March 2026, its total issued share capital comprises 535,653,205 ordinary shares, with no shares held in treasury, resulting in a total of 535,653,205 voting rights. This figure will serve as the denominator for shareholders to determine notification requirements under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Disclaimer*</description>
</item>
<item>
<title>Cairn Homes Plc: Cairn Homes Plc: Director/PDMR Shareholding</title>
<link>https://6ix.com/company/cairn-homes-plc/news/cairn-homes-plc-directorpdmr-shareholding</link>
<guid isPermaLink="true">https://6ix.com/company/cairn-homes-plc/news/cairn-homes-plc-directorpdmr-shareholding</guid>
<pubDate>Fri, 20 Mar 2026 08:00:00 GMT</pubDate>
<description>Cairn Homes plc announced that Chief Executive Officer Michael Stanley sold 3,500,000 ordinary shares on March 19, 2026, through a secondary placing in Dublin, Ireland, at a price of €2.20 per share, totaling €7,700,000. Following this transaction, Mr. Stanley retains 11,356,072 shares in the company.
Disclaimer*</description>
</item>
<item>
<title>Cairn Homes Plc: Cairn Homes Plc: Result of Secondary Placing</title>
<link>https://6ix.com/company/cairn-homes-plc/news/cairn-homes-plc-result-of-secondary-placing</link>
<guid isPermaLink="true">https://6ix.com/company/cairn-homes-plc/news/cairn-homes-plc-result-of-secondary-placing</guid>
<pubDate>Fri, 20 Mar 2026 07:00:00 GMT</pubDate>
<description>Cairn Homes Plc has announced the completion of a secondary placing where Michael Stanley sold 3.5 million shares at €2.20 per share, raising no proceeds for the company. This transaction, conducted via an accelerated bookbuild, is expected to settle on March 24, 2026. Following the sale, Michael Stanley will hold approximately 1.8 per cent. of the company's issued share capital.
Disclaimer*</description>
</item>
<item>
<title>Cairn Homes Plc: Cairn Homes Plc: Proposed Secondary Placing</title>
<link>https://6ix.com/company/cairn-homes-plc/news/cairn-homes-plc-proposed-secondary-placing</link>
<guid isPermaLink="true">https://6ix.com/company/cairn-homes-plc/news/cairn-homes-plc-proposed-secondary-placing</guid>
<pubDate>Thu, 19 Mar 2026 16:45:00 GMT</pubDate>
<description>Cairn Homes plc announced a proposed secondary placing where CEO Michael Stanley intends to sell up to 3.5 million shares, representing approximately 0.6% of the company's issued share capital. Following this sale, Mr. Stanley's stake will decrease from 2.4% to an estimated 1.8%, and he has agreed to a six-month lock-up period on his remaining shares. The placing will be conducted via an accelerated bookbuild process, with the final number of shares and price to be determined at the close of the</description>
</item>
<item>
<title>Regional Health Properties, Inc.: Sidoti Events, LLC's March Small-Cap Virtual Conference</title>
<link>https://6ix.com/company/regional-health-properties-inc/news/sidoti-events-llcs-march-small-cap-virtual-conference-1</link>
<guid isPermaLink="true">https://6ix.com/company/regional-health-properties-inc/news/sidoti-events-llcs-march-small-cap-virtual-conference-1</guid>
<pubDate>Wed, 18 Mar 2026 12:00:00 GMT</pubDate>
<description>Sidoti Events, LLC's March Small-Cap Virtual Conference.</description>
</item>
<item>
<title>Cairn Homes Plc: Cairn Homes Plc: Holding(s) in Company</title>
<link>https://6ix.com/company/cairn-homes-plc/news/cairn-homes-plc-holdings-in-company</link>
<guid isPermaLink="true">https://6ix.com/company/cairn-homes-plc/news/cairn-homes-plc-holdings-in-company</guid>
<pubDate>Tue, 10 Mar 2026 09:28:00 GMT</pubDate>
<description>JPMorgan Asset Management (UK) Limited has crossed a 6% threshold in Cairn Homes Plc, now holding a total of 7.09% of voting rights and financial instruments. This notification, dated March 10, 2026, reflects an acquisition of voting rights as of March 6, 2026, with the company's total voting rights standing at 625,576,122. The holding comprises 6.76% in shares and 0.33% through financial instruments, specifically cash-settled equity swaps. This represents an increase from their previous notific</description>
</item>
<item>
<title>Genflow Biosciences Plc: Genflow Biosciences PLC Announces Issue of Equity & PDMR Notifications</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-issue-of-equity-and-pdmr-notifications-6</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-issue-of-equity-and-pdmr-notifications-6</guid>
<pubDate>Thu, 05 Mar 2026 12:00:00 GMT</pubDate>
<description>THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ...</description>
</item>
<item>
<title>Cairn Homes Plc: Cairn Homes Plc: 2025 Preliminary Results</title>
<link>https://6ix.com/company/cairn-homes-plc/news/cairn-homes-plc-2025-preliminary-results</link>
<guid isPermaLink="true">https://6ix.com/company/cairn-homes-plc/news/cairn-homes-plc-2025-preliminary-results</guid>
<pubDate>Wed, 04 Mar 2026 07:00:00 GMT</pubDate>
<description>Cairn Homes Plc reported a strong financial performance for the year ended December 31, 2025, with revenue increasing by 10% to €944.6 million and operating profit rising by 12% to €168.6 million, driven by a 33% growth in their closed and forward order book to €1.32 billion. The company also saw a significant 19% increase in basic earnings per share to 21.3 cents and a 22% rise in dividend per share to 10.0 cents. Looking ahead, Cairn Homes is upgrading its FY26 guidance and expects to increase</description>
</item>
<item>
<title>Genflow Biosciences Plc: Genflow Biosciences PLC Announces Result of GM</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-result-of-gm</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-result-of-gm</guid>
<pubDate>Mon, 02 Mar 2026 12:55:00 GMT</pubDate>
<description>Results of General Meeting LONDON, UK / ACCESS Newswire / March 2, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") a leading European-based biotechnology company focusing on longevity, is pleased to announce that ...</description>
</item>
<item>
<title>Genflow Biosciences Plc: Genflow Biosciences PLC Announces Receipt of First Tranche of Grant</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-receipt-of-first-tranche-of-grant</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-receipt-of-first-tranche-of-grant</guid>
<pubDate>Mon, 02 Mar 2026 07:05:00 GMT</pubDate>
<description>THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ...</description>
</item>
<item>
<title>Farfetch Limited: Coupang Announces Results for Fourth Quarter 2025</title>
<link>https://6ix.com/company/farfetch-limited/news/coupang-announces-results-for-fourth-quarter-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/farfetch-limited/news/coupang-announces-results-for-fourth-quarter-2025-1</guid>
<pubDate>Thu, 26 Feb 2026 21:05:00 GMT</pubDate>
<description>SEATTLE, February 26, 2026--Coupang Announces Results for Fourth Quarter 2025</description>
</item>
<item>
<title>Cairn Homes Plc: Cairn Homes Plc: Block listing Interim Review</title>
<link>https://6ix.com/company/cairn-homes-plc/news/cairn-homes-plc-block-listing-interim-review</link>
<guid isPermaLink="true">https://6ix.com/company/cairn-homes-plc/news/cairn-homes-plc-block-listing-interim-review</guid>
<pubDate>Mon, 23 Feb 2026 17:16:00 GMT</pubDate>
<description>Cairn Homes Plc has provided its six-monthly interim review for the Save As You Earn (SAYE) plan, covering the period from August 8, 2025, to February 7, 2026. The company reported a balance of 185,609 unallotted securities from the previous return, with no increase to the block scheme and no securities issued or allotted during this period. Consequently, the balance of unissued or unallotted securities under the scheme remains at 185,609 at the end of the reporting period.
Discl</description>
</item>
<item>
<title>Farfetch Limited: Coupang to Announce Fourth Quarter 2025 Results on February 26, 2026</title>
<link>https://6ix.com/company/farfetch-limited/news/coupang-to-announce-fourth-quarter-2025-results-on-february-26-2026</link>
<guid isPermaLink="true">https://6ix.com/company/farfetch-limited/news/coupang-to-announce-fourth-quarter-2025-results-on-february-26-2026</guid>
<pubDate>Thu, 12 Feb 2026 21:05:00 GMT</pubDate>
<description>SEATTLE, February 12, 2026--Coupang to Announce Fourth Quarter 2025 Results on February 26, 2026</description>
</item>
<item>
<title>Genflow Biosciences Plc: Genflow Biosciences PLC Announces Preliminary Interim Results From Dog Study</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-preliminary-interim-results-from-dog-study</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-preliminary-interim-results-from-dog-study</guid>
<pubDate>Thu, 12 Feb 2026 07:00:00 GMT</pubDate>
<description>THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ...</description>
</item>
<item>
<title>Cairn Homes Plc: Cairn Homes Plc: Notice of 2025 Preliminary R...</title>
<link>https://6ix.com/company/cairn-homes-plc/news/cairn-homes-plc-notice-of-2025-preliminary-r</link>
<guid isPermaLink="true">https://6ix.com/company/cairn-homes-plc/news/cairn-homes-plc-notice-of-2025-preliminary-r</guid>
<pubDate>Wed, 11 Feb 2026 12:14:00 GMT</pubDate>
<description>Cairn Homes plc announced that its preliminary results for the period ending December 31, 2025, will be released on Wednesday, March 4, 2026. The results will be accessible on the company's website from 7:00 am GMT, with an audio webcast and conference call for analysts and investors scheduled for 8:00 am GMT on the same day.
Disclaimer*</description>
</item>
<item>
<title>Genflow Biosciences Plc: Notice of GM</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/notice-of-gm-19</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/notice-of-gm-19</guid>
<pubDate>Wed, 11 Feb 2026 07:00:00 GMT</pubDate>
<description>Genflow Biosciences Plc is considering a potential equity raise through private placements, seeking shareholder approval at a general meeting on March 2, 2026, to issue up to 188,947,368 new ordinary shares, approximately 38% of its current issued share capital. This would involve dis-applying pre-emption rights to facilitate the swift conclusion of the raise, the proceeds of which would fund the MASH program's IND-enabling stage, animal health payments, glaucoma proof-of-concept studies, and pa</description>
</item>
<item>
<title>Genflow Biosciences Plc: Genflow Biosciences PLC Announces Notice of GM</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-notice-of-gm</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-notice-of-gm</guid>
<pubDate>Wed, 11 Feb 2026 07:00:00 GMT</pubDate>
<description>THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ...</description>
</item>
<item>
<title>Genflow Biosciences Plc: Genflow Biosciences PLC Announces Holding(s) in Company</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-holding-132500387</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-holding-132500387</guid>
<pubDate>Fri, 30 Jan 2026 13:25:00 GMT</pubDate>
<description>LONDON, UK / ACCESS Newswire / January 30, 2026 / TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BP2C3V08 Issuer Name GENFLOW BIOSCIENCES PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal ...</description>
</item>
<item>
<title>Genflow Biosciences Plc: Holding(s) in Company</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/holdings-in-company-334</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/holdings-in-company-334</guid>
<pubDate>Fri, 30 Jan 2026 12:29:00 GMT</pubDate>
<description>Jonathan Mark Swann has increased his holding in Genflow Biosciences PLC, crossing a notification threshold on January 23, 2026. His total voting rights now stand at 12.13%, representing 59,861,278 shares, up from a previous notification of 11.32%. This acquisition of voting rights is the sole reason for the notification, with no financial instruments involved.
Disclaimer*</description>
</item>
<item>
<title>Genflow Biosciences Plc: Genflow Biosciences PLC Announces Administrative Approval of Grant & 2026 Priorities</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-administrative-approval-of-grant-and-2026-priorities</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-administrative-approval-of-grant-and-2026-priorities</guid>
<pubDate>Wed, 28 Jan 2026 07:00:00 GMT</pubDate>
<description>LONDON, UK / ACCESS Newswire / January 28, 2026 /THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK ...</description>
</item>
<item>
<title>Pacific Coast Oil Trust: Pacific Coast Oil Trust Announces Monthly Net Profits Interest Calculations</title>
<link>https://6ix.com/company/pacific-coast-oil-trust/news/pacific-coast-oil-trust-announces-monthly-net-profits-interest-calculations</link>
<guid isPermaLink="true">https://6ix.com/company/pacific-coast-oil-trust/news/pacific-coast-oil-trust-announces-monthly-net-profits-interest-calculations</guid>
<pubDate>Thu, 22 Jan 2026 22:24:00 GMT</pubDate>
<description>HOUSTON, January 22, 2026--PACIFIC COAST OIL TRUST (OTC–ROYTL) (the "Trust"), a royalty trust formed by Pacific Coast Energy Company LP ("PCEC"), announced today that there will be no cash distribution to the holders of its units of beneficial interest of record on January 28, 2026 based on the Trust’s calculation of net profits generated during November 2025 (the "Current Month") as provided in the conveyance of net profits interests and overriding royalty interest (the "Conveyance"). As furthe</description>
</item>
<item>
<title>Cairn Homes Plc: Cairn Homes Plc: Trading Update for the Year ...</title>
<link>https://6ix.com/company/cairn-homes-plc/news/cairn-homes-plc-trading-update-for-the-year</link>
<guid isPermaLink="true">https://6ix.com/company/cairn-homes-plc/news/cairn-homes-plc-trading-update-for-the-year</guid>
<pubDate>Tue, 20 Jan 2026 07:00:00 GMT</pubDate>
<description>Cairn Homes Plc reported a strong performance for the year ended 31 December 2025, with revenue reaching approximately €945 million, an increase of about 9.9% from €860 million in 2024. Operating profit rose by approximately 12.3% to around €168.5 million from €150.0 million, and Return on Equity (ROE) improved to approximately 16.6% from 15.1%. The company's forward order book increased to over 3,000 new homes valued at approximately €1.15 billion. Cairn Homes reaffirms its FY26 guidance, expec</description>
</item>
<item>
<title>Genflow Biosciences Plc: Genflow Biosciences PLC Announces Directorate Change</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-directorate-change</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-directorate-change</guid>
<pubDate>Mon, 19 Jan 2026 07:20:00 GMT</pubDate>
<description>THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ...</description>
</item>
<item>
<title>Genflow Biosciences Plc: Directorate change</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/directorate-change-227</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/directorate-change-227</guid>
<pubDate>Mon, 19 Jan 2026 07:00:00 GMT</pubDate>
<description>Genflow Biosciences Plc has appointed Gad Berdugo as its new Independent Non-Executive Chairman to drive corporate and R&D expansion, leveraging his extensive experience in biotechnology, capital markets, and company building, particularly in RNA-based therapeutics and LNP delivery. Mr. Berdugo, currently Managing Partner of Explorium Capital LLC, brings a strong track record from previous roles including CEO of EpiVax Oncology and Chief Business Officer at Editas Medicine. This strategic appoin</description>
</item>
<item>
<title>Cairn Homes Plc: Cairn Homes Plc: Notice of FY 2025 Trading Up...</title>
<link>https://6ix.com/company/cairn-homes-plc/news/cairn-homes-plc-notice-of-fy-2025-trading-up</link>
<guid isPermaLink="true">https://6ix.com/company/cairn-homes-plc/news/cairn-homes-plc-notice-of-fy-2025-trading-up</guid>
<pubDate>Fri, 09 Jan 2026 16:27:00 GMT</pubDate>
<description>Cairn Homes Plc has announced that it will release its trading update for the full year ended 31 December 2025 on Tuesday, 20 January 2026. This update will provide key financial figures and operational performance for the company. Investors will be looking for details on sales, profitability, and any forward-looking guidance that could impact the stock's valuation.
Disclaimer*</description>
</item>
<item>
<title>Farfetch Limited: RADAR Names Former PVH/Lululemon Executive Jonathan Aitken to Lead RFID Center of Excellence</title>
<link>https://6ix.com/company/farfetch-limited/news/radar-names-former-pvhlululemon-executive-jonathan-aitken-to-lead-rfid-center-of-excellence</link>
<guid isPermaLink="true">https://6ix.com/company/farfetch-limited/news/radar-names-former-pvhlululemon-executive-jonathan-aitken-to-lead-rfid-center-of-excellence</guid>
<pubDate>Fri, 09 Jan 2026 13:00:00 GMT</pubDate>
<description>NEW YORK, January 09, 2026--RADAR announced three leadership appointments and several internal promotions to support growing customer demand and global expansion.</description>
</item>
<item>
<title>Genflow Biosciences Plc: Review of 2025</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/review-of-2025</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/review-of-2025</guid>
<pubDate>Thu, 08 Jan 2026 07:00:00 GMT</pubDate>
<description>Genflow Biosciences PLC reported on its 2025 progress, highlighting advancements in its canine aging study (GF-1004) with no adverse events observed during the dosing phase and an initial efficacy readout expected in Q1 2026. The company also made strides with its MASH program (GF-1002), repositioning it for advanced fibrosis and generating preclinical data on HCC prevention, while exploring mRNA/LNP delivery. Genflow expanded into ophthalmology with a SIRT6-based gene therapy for glaucoma, targ</description>
</item>
<item>
<title>Regional Health Properties, Inc.: Regional Health Properties, Inc. Completes Additional Repurchases of 12.5% Series B Cumulative Redeemable Preferred Shares</title>
<link>https://6ix.com/company/regional-health-properties-inc/news/regional-health-properties-inc-completes-additional-repurchases-of-125percent-series-b-cumulative-redeemable-preferred-shares</link>
<guid isPermaLink="true">https://6ix.com/company/regional-health-properties-inc/news/regional-health-properties-inc-completes-additional-repurchases-of-125percent-series-b-cumulative-redeemable-preferred-shares</guid>
<pubDate>Mon, 05 Jan 2026 13:28:00 GMT</pubDate>
<description>Regional Health Properties, Inc. Completes Additional Repurchases of 12.5% Series B Cumulative Redeemable Preferred Shares.</description>
</item>
<item>
<title>Idaho Copper Corporation: Idaho Copper Corp. Announces 1:20 Reverse Stock Split to Support Uplisting Requirements</title>
<link>https://6ix.com/company/idaho-copper-corporation/news/idaho-copper-corp-announces-120-reverse-stock-split-to-support-uplisting-requirements</link>
<guid isPermaLink="true">https://6ix.com/company/idaho-copper-corporation/news/idaho-copper-corp-announces-120-reverse-stock-split-to-support-uplisting-requirements</guid>
<pubDate>Tue, 16 Dec 2025 18:40:00 GMT</pubDate>
<description>Idaho Copper Corp. Announces 1:20 Reverse Stock Split to Support Uplisting Requirements.</description>
</item>
<item>
<title>Genflow Biosciences Plc: Completion of Dosing Phase of Canine Gene Therapy</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/completion-of-dosing-phase-of-canine-gene-therapy</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/completion-of-dosing-phase-of-canine-gene-therapy</guid>
<pubDate>Tue, 16 Dec 2025 07:00:00 GMT</pubDate>
<description>Genflow Biosciences Plc has successfully completed the dosing phase of its canine gene therapy trial for its investigational SIRT6-based therapy, reporting no adverse events during administration, which demonstrates a strong safety and tolerability profile. The company anticipates a first efficacy read in mid-to-late January 2026, with a second assessment planned for June-July 2026, after which Genflow intends to resume discussions regarding potential early-stage licensing opportunities with ani</description>
</item>
<item>
<title>Genflow Biosciences Plc: Genflow Completes Dosing Phase of Canine Gene Therapy Trial</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/genflow-completes-dosing-phase-of-canine-gene-therapy-trial</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/genflow-completes-dosing-phase-of-canine-gene-therapy-trial</guid>
<pubDate>Tue, 16 Dec 2025 07:00:00 GMT</pubDate>
<description>THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ...</description>
</item>
<item>
<title>Genflow Biosciences Plc: Genflow to Attend Healthcare Conference</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/genflow-to-attend-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/genflow-to-attend-healthcare-conference</guid>
<pubDate>Thu, 11 Dec 2025 07:00:00 GMT</pubDate>
<description>Genflow Biosciences Plc announced its attendance at the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026, in San Francisco, aiming to engage with potential partners and investors regarding its longevity gene-therapy pipeline, specifically its SIRT6 longevity pathway focus and lipid nanoparticle delivery for mRNA SIRT6 therapeutics. The company's CEO highlighted the opportunity for strategic partnerships in the longevity space.
Disclaimer*</description>
</item>
<item>
<title>Cairn Homes Plc: Cairn Homes Plc: Board and Committee Membersh...</title>
<link>https://6ix.com/company/cairn-homes-plc/news/cairn-homes-plc-board-and-committee-membersh</link>
<guid isPermaLink="true">https://6ix.com/company/cairn-homes-plc/news/cairn-homes-plc-board-and-committee-membersh</guid>
<pubDate>Tue, 09 Dec 2025 07:00:00 GMT</pubDate>
<description>Cairn Homes plc has announced changes to its Board Committees effective January 1, 2026, following the retirement of Non-Executive Director Giles Davies after ten years of service. Linda Hickey will join the Nomination Committee and chair the Remuneration Committee, while Julie Sinnamon will join the Remuneration Committee and chair the Nomination Committee. Orla O’Connor will assume workforce engagement responsibilities. All committees will remain wholly independent. The company is also activel</description>
</item>
<item>
<title>Regional Health Properties, Inc.: Regional Health Properties Announces Series B Preferred Stock Repurchase Program</title>
<link>https://6ix.com/company/regional-health-properties-inc/news/regional-health-properties-announces-series-b-preferred-stock-repurchase-program</link>
<guid isPermaLink="true">https://6ix.com/company/regional-health-properties-inc/news/regional-health-properties-announces-series-b-preferred-stock-repurchase-program</guid>
<pubDate>Mon, 01 Dec 2025 21:01:00 GMT</pubDate>
<description>Regional Health Properties Announces Series B Preferred Stock Repurchase Program.</description>
</item>
<item>
<title>Regional Health Properties, Inc.: Regional Health Properties Reports Third Quarter 2025 Results Following Completion of Merger with SunLink Health Systems, Inc.</title>
<link>https://6ix.com/company/regional-health-properties-inc/news/regional-health-properties-reports-third-quarter-2025-results-following-completion-of-merger-with-sunlink-health-systems-inc</link>
<guid isPermaLink="true">https://6ix.com/company/regional-health-properties-inc/news/regional-health-properties-reports-third-quarter-2025-results-following-completion-of-merger-with-sunlink-health-systems-inc</guid>
<pubDate>Thu, 20 Nov 2025 22:05:00 GMT</pubDate>
<description>Regional Health Properties Reports Third Quarter 2025 Results Following Completion of Merger with SunLink Health Systems, Inc..</description>
</item>
<item>
<title>Movella Holdings Inc.: Xsens Announces New Xsens Link for Motion Capture Across Humanoid Robotics, Health, Sports, and Entertainment</title>
<link>https://6ix.com/company/movella-holdings-inc/news/xsens-announces-new-xsens-link-for-motion-capture-across-humanoid-robotics-health-sports-and-entertainment</link>
<guid isPermaLink="true">https://6ix.com/company/movella-holdings-inc/news/xsens-announces-new-xsens-link-for-motion-capture-across-humanoid-robotics-health-sports-and-entertainment</guid>
<pubDate>Wed, 12 Nov 2025 09:00:00 GMT</pubDate>
<description>Next-Generation motion capture from Xsens combines smarter sensors, seamless connectivity, and adaptive design to deliver precise, real-world motion data. ENSCHEDE, NL / ACCESS Newswire / November 12, 2025 / Xsens, a Movella brand and world leader ...</description>
</item>
<item>
<title>Regional Health Properties, Inc.: Regional Health Properties, Inc. Reports Sale of Skilled Nursing Facility</title>
<link>https://6ix.com/company/regional-health-properties-inc/news/regional-health-properties-inc-reports-sale-of-skilled-nursing-facility</link>
<guid isPermaLink="true">https://6ix.com/company/regional-health-properties-inc/news/regional-health-properties-inc-reports-sale-of-skilled-nursing-facility</guid>
<pubDate>Mon, 10 Nov 2025 19:45:00 GMT</pubDate>
<description>Regional Health Properties, Inc. Reports Sale of Skilled Nursing Facility.</description>
</item>
<item>
<title>Farfetch Limited: Coupang Announces Results for Third Quarter 2025</title>
<link>https://6ix.com/company/farfetch-limited/news/coupang-announces-results-for-third-quarter-2025</link>
<guid isPermaLink="true">https://6ix.com/company/farfetch-limited/news/coupang-announces-results-for-third-quarter-2025</guid>
<pubDate>Tue, 04 Nov 2025 21:05:00 GMT</pubDate>
<description>SEATTLE, November 04, 2025--Coupang Announces Results for Third Quarter 2025</description>
</item>
<item>
<title>Genflow Biosciences Plc: Genflow Biosciences PLC Announces Total Voting Rights</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-total-voting-rights</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-total-voting-rights</guid>
<pubDate>Fri, 31 Oct 2025 08:00:00 GMT</pubDate>
<description>LONDON, UK / ACCESS Newswire / October 31, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of ...</description>
</item>
<item>
<title>Genflow Biosciences Plc: Genflow Biosciences PLC Announces Second European Patent Application</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-second-european-patent-application</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-second-european-patent-application</guid>
<pubDate>Wed, 22 Oct 2025 06:00:00 GMT</pubDate>
<description>THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ...</description>
</item>
<item>
<title>Genflow Biosciences Plc: Second European Patent Application</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/second-european-patent-application</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/second-european-patent-application</guid>
<pubDate>Wed, 22 Oct 2025 06:00:00 GMT</pubDate>
<description>Genflow Biosciences Plc announced the publication of its second European patent application, Application No. 23821586.7, Publication No. EP4630038, titled "SIRT6 Variant for NASH," in the European Patent Bulletin. This confers provisional protection under Article 67(3) of the European Patent Convention, enabling Genflow to claim retroactive damages in designated EPC states for infringing acts occurring after the publication date, once the patent is formally granted. This publication complements </description>
</item>
<item>
<title>Farfetch Limited: Coupang to Announce Third Quarter 2025 Results on November 4, 2025</title>
<link>https://6ix.com/company/farfetch-limited/news/coupang-to-announce-third-quarter-2025-results-on-november-4-2025</link>
<guid isPermaLink="true">https://6ix.com/company/farfetch-limited/news/coupang-to-announce-third-quarter-2025-results-on-november-4-2025</guid>
<pubDate>Tue, 21 Oct 2025 20:05:00 GMT</pubDate>
<description>SEATTLE, October 21, 2025--Coupang to Announce Third Quarter 2025 Results on November 4, 2025</description>
</item>
<item>
<title>Genflow Biosciences Plc: Genflow Biosciences PLC Announces Recognition of Patentability of Claims</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-recognition-of-patentability-of-claims</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-recognition-of-patentability-of-claims</guid>
<pubDate>Mon, 20 Oct 2025 06:00:00 GMT</pubDate>
<description>THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ...</description>
</item>
<item>
<title>Genflow Biosciences Plc: Recognition of Patentability of Claims</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/recognition-of-patentability-of-claims</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/recognition-of-patentability-of-claims</guid>
<pubDate>Mon, 20 Oct 2025 06:00:00 GMT</pubDate>
<description>Genflow Biosciences Plc announced that its European patent (No. 22808414.1, Publication No. EP4338267) was officially published in the European Patent Office Bulletin on October 15, 2025. The European publication number EP4630038 appeared in the Bulletin, signifying that the patent application entered its final pre-grant phase under Article 67(3) EPC. With this publication, provisional protection took effect across participating EPO member states, allowing Genflow to enforce protection following</description>
</item>
</channel>
</rss>